Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Aliment Pharmacol Ther. 2021 Sep 8;54(10):1278–1289. doi: 10.1111/apt.16599

Figure 1. Flow chart summarising the enrolment criteria for each study group (number of patients in each group is also provided).

Figure 1.

SNVA: seronegative villous atrophy; VA: villous atrophy; SNCD: seronegative coeliac disease; GFD: gluten-free diet; CD: coeliac disease; tTG: tissue transglutaminase antibodies; EmA: endomysial antibodies; DGP: deamidated gliadin antibodies

* These patients had confirmed villous atrophy, DQ2/DQ8 positive HLA typing and a satisfactory clinical response to a gluten-free diet.